| Name | Title | Contact Details |
|---|
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders.
IgGenix is an early-stage, venture backed biotechnology company founded on breakthrough advances in Steve Quake`s laboratory at Stanford in collaboration with allergy clinician and researcher Kari Nadeau.
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. We have one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which prevents viral entry into healthy T-cells by blocking the HIV co-receptor CCR5. The drug candidate is also being tested for other immunological conditions, and has been granted FDA orphan drug status for the treatment of Graft versus Host Disease (GvHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow stem cell transplantation.
Kailos Genetics, the maker of Praxis, provides consumers access to affordable physician-ordered genetic tests. It is our mission to help people take control of their health and make more informed decisions through identifying risks to common medications. Praxis is an easily accessible form of personalized medicine catered to your lifestyle.
Azitra, Inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease.